Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) includes Pifeltro (doravirine) in a three-drug single-tablet regimen.
Researchers conducted a systematic review of antiretroviral treatment outcomes since 1994 among 78,000 people with HIV.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
This finding came from a larger report indicating that U.S. residents are increasingly taking drugs linked to such symptoms.
In a randomized comparison trial, those who switched from Epzicom to Descovy had a comparable rate of HIV suppression.
A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.
The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.
A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.
The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
Multi-antiretroviral combination tablets appear to combat HIV no better than regimens that include individual tablets.
The U.S. Food and Drug Administration has given the green light to Triumeq, ViiV Healthcare’s single-tablet, triple-combination antiretroviral...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.